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coeconomic studies based in China. Methods: A systematic literature
search was conducted using PubMed, Web of Science, Google Scholar,
and China National Knowledge Infrastructure to identify pharmacoe-
conomic studies conducted in China. The keywords included different
combinations of health economics, pharmacoeconomic, cost-effec-
tiveness, and China. The inclusion criteria for the studies were:
1) original research articles; 2) written/published in English; 3) com-
paring a pharmaceutical to another pharmaceutical, treatment
modality, or no treatment; and 4) conducted in China. The articles
were reviewed by two independent reviewers using the 100-point
Quality of Health Economic Studies scale for pharmacoeconomic
studies. General and economic analysis information was collected
from the articles. Results: A total of 20 studies were included, which
were published in 11 different journals between 2006 and 2012 and
had an average of 5  2 authors. The mean Quality of Healthee front matter Copyright & 2014, International S
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8712.Economic Studies scale scores for pharmacoeconomic studies was
80  10. More than two-thirds of the authors resided in China (70%)
and most had a medical background (90%). Most studies were
published in foreign journals (not based in China) (90%), conducted
cost-effectiveness (65%) or cost-utility analyses (65%), and used
modeling as their study design (80%). Conclusions: China-based
pharmacoeconomic studies written in English are limited in number,
but, on average, are of good quality. Economic evaluation of pharma-
ceuticals should be encouraged in China because appropriate alloca-
tion of health care resources is important in a country where, despite
economic growth, resources remain scarce relative to needs.
Keywords: China, cost-effectiveness analysis (CEA), pharmaco-
economics, Quality of Health Economic Studies (QHES).
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Health care is a major concern for Chinese people. “It is too hard
to seek health care and it is too expensive to pay for it!” is a
common complaint from this large population with unmet
medical needs. Several initiatives addressed this issue during
the health care reforms of 2006. A government-run insurance
program, the New Cooperative Medical Scheme, covered 86% of
the rural population within a year of implementation. Attempts
at supporting community health centers have been made to
redirect urban patients from large hospitals to community health
centers. Approximately $25 to $38 billion in government funding
had been injected to provide universal basic health care [1].
Although these initiatives mitigated some problems, there are
still concerns due to the increasing cost and inefﬁciencies in the
health care delivery system. van Doorslaer et al. [2] found that
increased out-of-pocket health spending puts an additional 19%
people below the poverty line. It has been estimated that 35% and
43% of urban and rural households, respectively, have difﬁculties
in paying for their health care [3]. A study by Yip and Mahal [4]found that the cost of hospitalization can be nearly seven times
the annual income of a low-income person in the rural areas and
four times that in the urban areas. Liu and Mills [5] noted
substantial overprescribing of medications and ordering of
expensive services when remuneration to physicians was based
on the quantity of services provided and the revenue generated
by them. These unnecessary services drive up the costs associ-
ated with health care. Other problems involve inadequate
insurance coverage, inequality, and inefﬁcient use of scarce
resources [6].
Currently, China is going through an important phase of
transformation in its health care system. Pharmacoeconomic
research could be important at this crucial time by providing
insights in managing health care costs and ensuring optimal use
of scarce resources. This is especially important in a developing
country such as China where the gap between required and
available resources for health care is wide and continues to
widen. For countries such as China, economic evaluations of
health care resources can serve as useful tools in resource
allocation and decision making. Such research could also helpociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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making. The results assessing clinical outcomes and economic
beneﬁts could provide guidance to health care providers in
selecting appropriate treatment plans and provide more trans-
parency in decision making.
To our knowledge, no published study (in English) has sys-
tematically reviewed pharmacoeconomic studies conducted in
China. Thus, the objective of this study was to evaluate the
extent and quality of published pharmacoeconomic research
in China.Methods
Literature Search
A systematic search of the literature was conducted in December
2012 using PubMed, MEDLINE, Web of Science, and Google
Scholar to identify pharmacoeconomic studies pertaining to
China. Search terms included “pharmacoeconomic,” “health
economic,” “cost,” “cost-effectiveness analysis,” “cost-minimiza-
tion analysis,” “cost-utility analysis,” “cost-beneﬁt analysis,”
“economics,” “pharmacy,” “pharmaceuticals,” and “China.” These
keywords were used alone and in different combinations. The
inclusion criteria for this study were as follows: 1) original
studies; 2) carried out comparisons between pharmaceuticals,
treatment modality, or against no treatment; 3) conducted in
China (including Hong Kong); and 4) manuscript written/pub-
lished in English. Studies comparing multiple countries were
excluded. Articles were excluded if cost was not the main topic
of the study. Reference lists of these articles were used to identify
additional relevant articles. Full journal publication was required
for a study to be included in this review; thus, meeting abstracts,
letters to the editor, treatment guidelines or recommendations,
expert opinion, and narrative reviews were excluded.
Two researchers (S.J. and X.M.) carried out the literature
search using the English-based search engines and identiﬁed
articles independently. They assessed the abstracts of the iden-
tiﬁed studies, and all abstracts that met the inclusion criteria
were conﬁrmed by a third researcher (P.D.). Full articles were then
obtained for further evaluation. To examine and compare the
number of articles written in Chinese that were not included in
English-based search engines, a fourth researcher (L.Y.) used the
China National Knowledge Infrastructure search engine to deter-
mine the number of articles written in Chinese up to 2012 using
the same key words in Chinese.
Evaluation of Studies
A data collection form similar to the one developed by Gavaza
et al. [7], which has been used in several previous studies [8–10],
was used to collect general and economic information. General
information included the total number of authors for the study,
country of residence of the primary author, primary training of
ﬁrst author, year of publication of the study, journal in which the
study was published, and type of publication. Economic informa-
tion included type of costs, perspective of study, method of
economic evaluation deﬁned in study, study design, primary
outcomes, type of data, disease state investigated, funding
source, type of medical function, and the decision reached on
whether treatment was cost-effective.
We used the Quality of Health Evaluation Studies (QHES) scale
to assess full pharmacoeconomic studies [11,12]. The QHES scale
is a 16-item scale covering evaluation of study objectives, per-
spective, economic model, study design, and methodology. Each
item is weighted appropriate to its importance in assessing
quality. The QHES scale is a 100-point scale, with lower scoresrepresenting poor quality. A modiﬁed version of the Quality of
Health Economic Survey instrument was used. Instead of using a
zero versus full-score technique, three scoring points—full score,
a midpoint score, or a zero—were used [8]. Two blinded reviewers
assessed each article independently. All disagreements were
resolved through discussions and assessment by a third reviewer.
If the difference between the scores given by the two reviewers
exceeded 10, it was passed to a third reviewer for further
evaluation. In this case, the ﬁnal score of the article was deﬁned
as the average score of the third reviewer and a closer score given
by either reviewer.
Statistical Analysis
Descriptive statistics were reported for all the variables. The
differences in QHES scale scores by variables (country of resi-
dence of the primary author, type of publication, geographic
location, funding source, and type of medical function) were
compared using independent sample t tests. The difference in
QHES scale scores by type of data collection was compared using
analysis of variance. The relationship between the QHES scale
and the number of authors and the year of publication was
assessed using Pearson’s correlation coefﬁcient. The alpha level
was set at 0.05. All statistical analyses were conducted using SPSS
version 20.Results
The literature search using both English-based and Chinese-
based search engines identiﬁed almost 6000 (5943) abstracts,
but only 97 were available in English. After reviewing the
abstracts of these 97 articles, 62 articles were excluded because
of being multiple-country comparisons (n ¼ 13), having no cost
analyses (n ¼ 36), being a cost-of-illness study (n ¼ 7), or a review
article (n ¼ 6). Fifteen studies were further excluded because
although the abstract was available in English, the full article was
written in Chinese (n ¼ 11) and the study did not compare
pharmaceutical products (n ¼ 4). Therefore, a total of 20 studies
were included for further evaluation (Fig. 1 and Table 1).
The earliest article was published in 2006, and the latest one
was published in 2012 (Fig. 2). The 20 articles were published in 11
different journals based in the United Kingdom (n ¼ 9), the United
States (n ¼ 5), China (n ¼ 2), The Netherlands (n ¼ 2), and Japan
(n ¼ 2). More than half (60%; n ¼ 12) of the articles were published
in medical journals, and the other articles (40%; n ¼ 8) were
published in health/medical economic journals. Articles had an
average of ﬁve authors (mean 5  2). On the basis of institutional
afﬁliation, most of the primary authors (i.e., ﬁrst authors) were
from China (70%; n ¼ 14) and had medical or clinical training
(90%; n ¼ 18). Nationwide studies accounted for 70% of the
studies (n ¼ 14), and the rest were subnational studies (Table 2).
The articles discussed various disease states including cancer
(n ¼ 7), hepatitis (n ¼ 4), cardiovascular disease (n ¼ 3), diabetes
(n ¼ 2), inﬂuenza (n ¼ 2), schizophrenia (n ¼ 1), and enterovirus71
infection (n ¼ 1). More than half of the studies (n ¼ 13; 65%)
assessed disease treatment. The most common perspective was
the third-party payer (n ¼ 12, 60%). Economic evaluation was the
primary objective for all the included studies. Most of the studies
(n ¼ 13; 65%) conducted cost-effectiveness analysis, and 10
articles (50%) conducted both cost-effectiveness analysis and
cost-utility analysis. Three articles (15%) conducted cost-
minimization analysis, and only one article conducted cost-
beneﬁt analysis. Most studies used modeling (n ¼ 16; 80%) for
their analyses. All the studies included direct medical costs, but
only two (10%) included direct nonmedical costs, and two (10%)
included indirect costs. In addition, 18 (90%) studies used
Arcles inially idenﬁed 
from database (n = 97)*
Arcles included aer 
reviewing abstract (n = 35)
Arcles included in our 
study (n = 20)
First step: Excluded arcles (n = 62)
Mulple-country comparison (13)
Nonpharmacoeconomic study (36)
Systemac review (n = 6) 
Cost of illness study (n = 7)
Second step: Excluded arcles (n = 15)
Abstract in English, arcle in Chinese
(n = 11)
No comparison of pharmaceucals or 
treatment modality (n = 4)
Fig. 1 – Article selection process. *5943 abstracts were also found by the Chinese search engine but were excluded in our study
because they were not available in English.
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studies used both primary and secondary data. Most studies were
funded by government (35%) or the pharmaceutical industry
(30%) (Table 3).
The mean QHES scale scores for the 20 pharmacoeconomic
studies was 80  10 out of 100, ranging from 59 to 96. Although
none of the QHES scale comparisons (Table 4) were statistically
signiﬁcantly different, articles with ﬁrst authors residing in
foreign countries had a slightly higher mean QHES scale score
than did those written by Chinese authors (82 vs. 80); articles that
were published in health/medical economic journals had a
higher QHES scale score than did those published in medical
journals (83 vs. 79); subnational studies had a higher QHES scale
score than did national studies (81 vs. 80); and industry-funded
studies had a slightly higher score than did nonindustry studies
(81 vs. 80).Discussion
General and Economic Characteristics
In this study, the characteristics and quality of pharmacoeco-
nomic studies in China that were available in English were
summarized and presented. Similar to the articles that reviewed
published studies from Russia (n ¼ 16) [9], India (n ¼ 29) [8], and
Zimbabwe (n ¼ 26) [7], our study had a low number of published
full pharmacoeconomic studies (n ¼ 20). This number is lower
than the number of reviews from other Asian countries such as
Korea (n ¼ 45) [13] and Thailand (n ¼ 41) [14], although it is
acknowledged that we used stricter inclusion criteria. Although
the earliest article based on the search was published in 1990,
these early studies were mostly written in Chinese and were of
low quality. The earliest study based on our criteria (available in
English) was published in 2006. In addition, as shown in Fig. 2,there was a reduction in the number of articles from 2010 to 2012.
This is possibly due to the development of pharmacoeconomic
journals in Chinese and the transfer of publications to Chinese
journals. We found a large number (n ¼ 5846) of abstracts
through our literature search that were written in Chinese.
It was not within the scope of this study to assess the quality
of articles written in Chinese. The preference for Chinese lan-
guage publications for Chinese authors is likely because Chinese
is the language predominantly used for academic and govern-
ment communication in China because it is more widely under-
stood compared with English. In addition to the language issues
mentioned above, the limited number of English-based pharma-
coeconomic studies in China is likely due to the unavailability of
retrospective data or difﬁculty in conducting studies in which
primary data are collected. This is supported by the fact that
most of the studies (80%) used modeling. This rate is closest to
that reported in the Korean study (47%) but still much higher.
In modeling studies, variables were estimated from hospital data,
expert options, and literature. Although justiﬁcations for data
extraction were stated in 80% of the modeling studies, caution
should still be exercised when interpreting the results. Most of
the models were built in European countries and adapted to the
Chinese studies. Although the modeling studies aim to use as
much Chinese data as possible, which is obtained from local
institutes such as hospitals, oftentimes because of the paucity of
these data, some non-Chinese estimates are extracted from the
literature. This highlights the need for collection/availability of
more Chinese data at the local level to improve the representa-
tiveness and usefulness of the pharmacoeconomic studies.
In addition, little is known about the extent of pharmacoeco-
nomic education in China [15]. To our knowledge, pharmaco-
economics is not one of the mandatory courses in most of the
pharmacy schools and may be neglected in pharmacy schools in
China. It is even more limited in pharmacy-related undergradu-
ate education. The inadequacy of pharmacoeconomic education
Table 1 – Articles evaluated in this study (n ¼ 20).
First author,
year
Type of
analysis
Perspective Description of
intervention
Outcome
measure
Results
Chen, 2009 [21] CEA China health
insurance
system
Adjuvant trastuzumab
treatment group vs.
standard adjuvant
chemotherapy in
treating HER2-positive
early breast cancer
LYG; The ICERs for LYG were US
$7,564, US $7,933, and US
$7,929 in Beijing, Shanghai,
and Guangzhou; The ICERs
for QALY were US $7,676,
US $8,049, and US $8,046
CUA QALY
Chen, 2009 [22] CEA Chinese public
health care
Imatinib vs. interferon-α
for patients with newly
diagnosed chronic-
phase chronic myeloid
leukemia
LYG; The ICER comparing imatinib
with interferon was RMB
73,674 (US $10,786) per
QALY. Imatinib is more
cost-effective than
interferon.
CUA QALY
Huang, 2011 [23] CEA NA High-dose arabinoside
(HiDAC) vs.
daunorubicin- based
treatment
Event-free
survival;
Cost per LYS of HiDAC is
$18,747 for patients with
better/intermediate
cytogenetic risk. For this
population, HiDAC-based
therapy is cost-effective.
LYS
Hutton, 2010 [24] CUA Societal Hepatitis B catch-up
vaccination program
for children and
adolescents in China
QALY Hepatitis B catch-up
vaccination for children
and adolescents in China is
cost-saving.
Lee, 2010 [25] CUA Third-party payer Enterovirus 71 vaccine vs.
no enterovirus 71
vaccine
DALYs Routine vaccinations are
cost-effective when
vaccine cost is $25 and
efﬁcacy is 470% or cost is
$10 and efﬁcacy is450% at
a threshold of per-capita
GDP in China.
Lee, 2009 [26] CEA Both payer and
societal
perspective
7vPCV vaccination vs. no
vaccination
The number of
cases of
invasive
pneumococcal
The incremental cost per LYG
of 7vPCV is $6,460 from a
payer perspective and
$5,929 from the societal
perspective. 7vPCV is a
cost-effective intervention.
disease (IPD) and
deaths avoided;
LYG
Lee, 2006 [27] CMA Public health
organization
Clopidogrel plus aspirin
vs. aspirin alone
Assumed same,
just measured
costs
Costs between clopidogrel
plus aspirin vs. aspirin
alone are similar.
Levin, 2010 [28] CEA Societal Rapid human
papillomavirus (HPV)-
DNA screening test for
cervical cancer
prevention in the high-
risk region of Shanxi,
China
LYS The increment cost was US
$150 per LYS; it is very
cost-effective evaluated
against China’s per-capita
GDP (US $1,702).
Li, 2010 [29] CMA NA New vs. old diagnosis
approaches to
vasovagal syncope in
children and
adolescents
Assumed same—
just compared
costs
The costs of hospitalization
and diagnostic test were
RMB 1,097 (US $161) less for
the new diagnostic
approach.
Palmer, 2008 [30] CEA Third-party payer Biphasic insulin aspart 30
(BIAsp30) vs. biphasic
human insulin
LYG The ICER of BIAsp30 is RMB
1,926 (US $281) per QALY
gained. BIAsp30 in patients
with poorly controlled type
2 diabetes is cost-effective.
CUA QALY
Peng, 2009 [31] CEA Chinese health
care provider
Doxorubicin/
cyclophosphamide vs.
docetaxel/
cyclophosphamide in
LYG; The ICER was RMB 26,742 (US
$ 3,915) per LYG and RMB
24,305 (US $3,558) per QALY
gained. Docetaxel/
cyclophosphamide may be
CUA QALY
continued on next page
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Table 1 – continued
First author,
year
Type of
analysis
Perspective Description of
intervention
Outcome
measure
Results
treating operable breast
cancer
considered cost-effective
from a Chinese health care
provider perspective.
Wu, 2010 [32] CUA Chinese social
security
program
Nucleoside analogue
therapy for hepatitis B
treatment
QALY The entecavir strategy had
improved cost-
effectiveness in 490% of
the cases. (Cost-
effectiveness thresholds
were below approximately
$11,000 per QALY.)
Wu, 2011 [33] CEA China health care
system
Adding rh-endostatin to
standard
chemotherapy vs.
standard
chemotherapy in
patients with advanced
non–small cell lung
cancer
Disease-free LYG; The total increased by 0.09,
0.37, 0.60, and 0.63 y after 1,
2, 5, and 10 y. The ICER for
adding rh-endostatinto
chemotherapy was
$24,454/QALY gained. It is
unlikely to be cost-
effective.
CUA Total LYG;
QALY
Wu, 2012 [34] CEA China health care
system
Trastuzumab in
combination with
chemotherapy vs.
traditional
chemotherapy for
HER2-positive
advanced gastric or
gastro-esophageal
junction cancer
LYG; The ICER was $251,667/QALY
gained. Trastuzumab was
not cost-effective.
CUA QALY
Xie, 2008 [35] CUA A health-care
perspective
Intensive blood glucose
control with metformin
vs. usual care
QALY Intensive blood glucose
control is likely to be cost-
effective at a threshold of
RMB 134,900 (US $19,751).
Yang, 2009 [36] CEA Chinese health
care system
Long-acting risperidone
injection vs. alternative
atypical antipsychotic
agents
Successfully
treated patient
Long-acting risperidone is
more cost-effective than
are olanzapine and
queriapine.
You, 2009 [37] CBA Hong Kong public
health
organization
Inﬂuenza vaccination vs.
inﬂuenza plus
pneumococcal
vaccination vs. no
vaccination
Dollars (beneﬁt-
cost ratio);
Comparing inﬂuenza
vaccination plus
pneumococcal to inﬂuenza
vaccination, the
incremental cost is $500
per additional QALY. Two
vaccine strategies are likely
to cost less and gain higher
QALYs than no vaccine.
The beneﬁt-cost ratios for
inﬂuenza vaccination and
inﬂuenza plus
pneumococcal vaccination
are 6.39 and 5.10.
CUA QALY
Yuan, 2008 [38] CEA CUA China social
security
program
Entecavir monotherapy
vs. lamivudine
monotherapy
LYG; Comparing entecavir to
lamivudine, the ICER is
RMB 5,368 (US $785) per
QALY. Entecavir is cost-
effective.
QALY
Zhou, 2011 [39] CMA Health care
provider
Antibiotics in coronary
artery bypass grafting
vs. no antibiotics
Assumed same,
just measured
costs
The average total hospital
cost and medication cost
were RMB 7,752 (about US
$1,134) and RMB 2,836
(about US $415) less for
patients who used
antibiotics.
continued on next page
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Table 1 – continued
First author,
year
Type of
analysis
Perspective Description of
intervention
Outcome
measure
Results
Zhuang, 2008 [40] CEA Health system
and societal
Low-cost hepatitis A
vaccine vs. no vaccine
for children
LYS; Vaccination gained QALYs
and is more cost-
effectiveness in the lower
infection regions.
CUA QALY
CBA, cost-beneﬁt analysis; CEA, cost-effectiveness analysis; CMA, cost-minimization analysis; CUA, cost-utility analysis; DALY, disability-
adjusted life-years; GDP, gross domestic product; ICER, incremental cost-effectiveness ratio; LYG, life-year gained; LYS, life-year saved; QALY,
quality-adjusted life-year.
Table 2 – General information for included studies
(n ¼ 20).
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publications. Lack of attention to health economic evaluations
could be another contributing factor. After the health care
reforms in 2006 were passed to help address the inefﬁciencies
in the system and the affordability problems, pharmacoeconomic
evaluations have increased substantially. The overall extent of
pharmacoeconomic studies in China, however, is still limited
compared with that in other Asian countries. At this time, there
are no mandatory requirements for pharmacoeconomic assess-
ments, although these evaluations have been included in a recent
health care reform plan. Pharmacoeconomic evaluation can have
a substantial impact on several aspects of the health care reform
in China (2009), such as guidance of drug pricing, promotion of
health insurance reimbursement, and rational use of drugs. In
addition, pharmacoeconomics can provide strong evidence for
the selection of essential drugs for the National Essential Drug
List, as well as the best therapy for patients. Guidelines for China
have been published on the International Society of Pharmacoe-
conomics and Outcomes Research Web site [16].
The study results showed that only a small proportion of the
articles were published in domestic (i.e., Chinese) journals (n ¼ 2
or 10%). This rate is lower than that for reviews from other Asian
countries such as Thailand (33%) [14] and India (31%) [8], but
similar to that for Nigeria (14%) [10]. This suggests that China is
lagging behind other Asian countries in the availability of
domestic English language journals in which to publish pharma-
coeconomic studies. In addition, perhaps pharmacoeconomic
studies are not given a high priority by the existing Chinese
journals that are available in English. This also raises the
question whether the remaining 90% of the pharmacoeconomicFig. 2 – Number of articles published in each year.studies published in foreign journals are reaching the intended
audience—Chinese health care providers and decision makers.
Because 70% of the ﬁrst authors resided in China, the accessibility
to foreign journals for Chinese researchers and clinicians might
be an issue.
Cost-effectiveness (65%) and cost-utility (65%) analyses were
the most frequently used methods of economic evaluation. Only
one study conducted a cost-beneﬁt analysis. Cost-beneﬁt studies
are complex, and the low number of cost-beneﬁt studies may
reﬂect the lack of knowledge and experience in using this
method.
According to He et al. [17], the nonaccidental leading causes of
death in China are vascular diseases (cardiovascular and cere-
brovascular), cancer, and infectious disease. Vascular diseases
and cancer are also the most burdensome diseases. The most
common diseases studied in our review were cancer (n ¼ 7),
infectious disease (n ¼ 4), and cardiovascular disease (n ¼ 3),
which are consistent with the top causes of death in China. This
result shows that pharmacoeconomic studies in China have been
focusing on the most burdensome diseases.
A higher percentage (85%) of studies listed the funding source
when compared with reviews from Thailand (68%) [14], Nigeria
(45%) [10], and Zimbabwe (35%) [7]. This may indicate a better
transparency in the conduct of research and perhaps more
reliability in the results. The two most common sources ofCategories n (%)
Country of residence of the primary author
China 14 (70)
Other* 6 (30)
Primary training of ﬁrst author
Medical/clinical 18 (90)
Business/economics 2 (10)
Country of journal
China 2 (10)
Japan 2 (10)
The Netherlands 2 (10)
United Kingdom 9 (45)
United States 5 (25)
Type of publication
Medical 12 (60)
Health/medical economic 8 (40)
Geographic location covered
National 14 (70)
Subnational (30)
* United States of America, Switzerland, and Denmark.
Table 4 – Relationship of study characteristics with
Quality of Health Economic Studies (QHES) scale
scores for full pharmacoeconomic analyses (n ¼ 20).
Variables Category (n) QHES,
mean 
SD*
Country of
residence of
the primary
author
China (14) 80  11
Other (6) 82  6
Type of
publication
Medical (12) 79  8
Health medical economic (8) 83  12
Geographic
location
National (14) 80  11
Subnational (6) 81  7
Type of data
collection
Primary data only (2) 72  12
Secondary data only (10) 82  8
Both primary data and
secondary data (8)
81  12
Funding source Pharmaceutical industry (6) 81  13
Nonindustry (11) 80  10
None (authors’ resources) (3) 80  6
Type of medical
function
Prevention/screening (6) 81  7
Treatment (13) 82  10
Diagnosis (1) 63 (NA)
NA, not applicable/available.
* QHES study scores: possible range ¼ 0–100; study range ¼ 59–96.
Table 3 – Economic evaluation information for
included studies (n ¼ 20).
Variables Categories n (%)
Method of economic
evaluation*
Cost-effectiveness
analysis (CEA)
13 (65)
Cost-utility analysis
(CUA)
13 (65)
Cost-beneﬁt analysis
(CBA)
1 (5)
Cost-minimization
analysis (CMA)
3 (15)
Type of costs* Direct medical costs 20 (100)
Direct nonmedical costs 2 (10)
Indirect costs 2 (10)
Study design Randomized controlled
trial (RCT)
1 (5)
Modeling 16 (80)
Retrospective database 2 (10)
Prospective cohort 1 (5)
Type of data collection* Primary data 10 (50)
Secondary data 18 (90)
Source of funding* Pharmaceutical industry 6 (30)
Author’s own resources 3 (15)
Government 7 (35)
Private not-for-proﬁt
organizations
2 (10)
Not listed 3 (15)
Type of medical
function
Prevention and screening 6 (30)
Diagnosis 1 (5)
Treatment 13 (65)
* Total is more than 100% because some studies fell into more
than one category.
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tics industry (30%).
Quality of the Studies
In general, the studies included in this review were of high
quality (QHES scale score ¼ 80 out of 100). The general and
economic characteristics did not signiﬁcantly relate with the
quality of studies. This could be likely due to the relatively small
sample size. To provide guidance and ensure the quality of future
pharmacoeconomic studies, a new checklist for health care–
related economic publications—the Consolidated Health
Economic Evaluation Reporting Standards—was unveiled and
discussed at the Annual International Society of Pharmaco-
economics and Outcomes Research meeting in May 2013 [18].
Future reviewers and authors are encouraged to use this
checklist.
Limitations
A limitation of this study is the small number of articles that met
the inclusion criteria. Most of the articles found in the literature
search were excluded because they were not available in English.
In addition, some abstracts were available in English but the full-
text articles were in Chinese and thus excluded. This exclusion
criterion reduces our ability to capture the overall quality of
studies in China. We also excluded the studies that did not
conduct any cost comparisons, which further reduced the num-
ber of studies. Another limitation is the potential threat of
publication bias because only published studies were included.
Previous studies have shown that positive results are more likelythan negative results to get published [19]. Also, because only
published research was included, any reports, agency work,
dossiers, consulting documents, and so forth that may be used
by clinicians and decision makers were not included. Finally,
other reviewers may score the studies differently, which could
lead to variation in the results.Conclusions
To our knowledge, this is the ﬁrst systematic review of phama-
coeconomic studies conducted in China. Overall, the number of
China-based pharmacoeconomic studies written in English was
limited, but, on average, of good quality. Economic evaluation of
pharmaceuticals should be encouraged in China because appro-
priate allocation of limited health care resources is important in a
country with large unmet medical needs. Improving education
and standardizing guidelines may help to increase the number of
pharmacoeconomic studies in China. To that end, in 2012, the
International Society of Pharmacoeconomics and Outcomes
Research has added Value in Health – Regional Issues Asia [20] to
its publication list. In addition, encouragement to publish articles
in English instead of Chinese would help to increase the acces-
sibility of pharmacoeconomic studies conducted in Chinese
populations. Overall, improving education, standardizing guide-
lines, and publishing in English should be encouraged in China to
promote the level of not only pharmacoeconomic research but
also other research areas of science.
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